Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$67.08 USD
+0.05 (0.07%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $67.50 +0.42 (0.63%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum C VGM
Gilead Sciences (GILD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$84.18 | $105.00 | $71.00 | 25.59% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Gilead Sciences comes to $84.18. The forecasts range from a low of $71.00 to a high of $105.00. The average price target represents an increase of 25.59% from the last closing price of $67.03.
Analyst Price Targets (22)
Broker Rating
Gilead Sciences currently has an average brokerage recommendation (ABR) of 2.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.14 a month ago based on 22 recommendations.
Of the 25 recommendations deriving the current ABR, 10 are Strong Buy, representing 40% of all recommendations. A month ago, Strong Buy represented 45.45%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 11 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 14 | 14 | 11 | 11 | 9 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.24 | 2.24 | 2.14 | 2.14 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
2/22/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
2/12/2024 | Needham & Company | Joseph R Stringer | Not Available | Hold |
2/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
2/7/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
1/8/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
11/9/2023 | Not Identified | Not Identified | Hold | Hold |
11/8/2023 | Not Identified | Not Identified | Not Available | Hold |
11/7/2023 | Not Identified | Not Identified | Hold | Hold |
10/11/2023 | SVB Securities | Daina M Graybosch | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.24 |
ABR (Last week) | 2.24 |
# of Recs in ABR | 25 |
Average Target Price | $84.18 |
LT Growth Rate | 13.30% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -1.14 |